Optus Pharmaceutical옵투스제약
131030 · KOSDAQ · ₩131030 · 옵투스제약
₩5,950▲ ₩100 (1.71%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩87B | ₩82B | ₩72B | ₩59B | ₩57B |
| Cost of sales | ₩39B | ₩37B | ₩31B | ₩27B | ₩25B |
| Gross profit | ₩48B | ₩45B | ₩41B | ₩32B | ₩33B |
| Operating income | ₩8.9B | ₩8.6B | ₩8.2B | ₩5.3B | ₩10B |
| Net income | ₩11B | ₩10B | ₩11B | ₩5B | ₩9.9B |
| Net income to shareholders | ₩11B | ₩10B | ₩11B | ₩5B | ₩9.9B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩191B | ₩167B | ₩149B | ₩136B | ₩140B |
| Current assets | ₩67B | ₩78B | ₩92B | ₩81B | ₩91B |
| Cash and equivalents | ₩21B | ₩27B | ₩18B | ₩10B | ₩33B |
| Total liabilities | ₩26B | ₩23B | ₩15B | ₩12B | ₩13B |
| Current liabilities | ₩26B | ₩21B | ₩13B | ₩9.8B | ₩11B |
| Total equity | ₩165B | ₩144B | ₩134B | ₩124B | ₩127B |
| Shareholders' equity | ₩165B | ₩144B | ₩134B | ₩124B | ₩127B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩16B | ₩8.9B | ₩12B | ₩2B | ₩7.1B |
| Capital spending | ₩45B | ₩12B | ₩3.3B | ₩6B | ₩11B |
| Free cash flow | −₩28B | −₩2.9B | ₩9.1B | −₩4B | −₩3.6B |
| Dividends paid | ₩0 | ₩1.5B | ₩1.5B | ₩1.6B | ₩1.6B |
Consolidated where available. Amounts in won.
Also known as: Optus Pharmaceutical / 옵투스제약 / 131030 / KRX:131030
Source: KRX statistical information